Singapore, 25 February 2025 – Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, today announced outstanding financial results for FY2024, achieving record revenue of S$195.4 million and net profit growth of 26.5% to S$10.9 million.
Financial Highlights Demonstrate Strong Growth Momentum
The Group delivered robust financial performance across all key metrics, with revenue increasing 14.6% year-on-year from S$170.6 million in FY2023. This growth was primarily driven by the Specialty Pharma Principals segment, which saw a 21.6% revenue increase to S$124.2 million. Gross profit rose 12.3% to S$69.5 million, while profit before tax grew 22.7% to S$13.0 million.
Reflecting confidence in its financial position, the Board proposed a final dividend of 1.50 Singapore cents per share, representing a significant 74.4% increase from the previous year’s 0.86 cents payout. This dividend represents 45.4% of net profits attributable to shareholders, exceeding the Group’s established 30% payout policy.
Strategic Business Segments Show Consistent Performance
Mr. Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, commented: “Our FY2024 results demonstrate the strength of our diversified business model and successful execution of growth strategies across all segments. The Specialty Pharma Principals business continues to be our key revenue driver, while our Proprietary Brands and digital healthcare platforms contribute meaningfully to our overall performance.”
The Proprietary Brands segment grew 7.4% to S$27.6 million, supported by strong demand for Ceradan® dermatological products and Ocean Health® supplements. The Medical Hypermart and Digital segment maintained steady growth with a 2.1% revenue increase to S$43.6 million.
Innovation and Expansion Drive Future Growth
FY2024 saw several strategic milestones, including:
- The successful launch of Ceradan® Advanced Hand Balm, developed in collaboration with A*STAR
- Expansion of Ocean Health® into Indonesia, Malaysia and Vietnam
- Exclusive licensing agreements for Wynzora® Cream and Amenalief® in ASEAN markets
- Acquisition of Ardence Pharma contributing S$7.2 million in revenue
- Digital platform WellAway processing 100,000 e-prescriptions
Navigating Challenges with Confidence
While acknowledging macroeconomic challenges including inflationary pressures and currency volatility, the Group remains optimistic about its ability to deliver sustainable growth. “Our strong fundamentals, diversified portfolio and strategic initiatives position us well to navigate market uncertainties while continuing to create value for stakeholders,” added Mr. Lim.
